Replimune Group, Inc. (REPL) · Aug 14, 2026 · Earnings

The approval is old news; now the launch bill starts showing up

Miss — EPS loss of $0.72 vs published consensus around $0.66–$0.68

A modest EPS miss is secondary to the real shift: Replimune is moving from development into commercial launch mode.

The quarter came in modestly worse than expected. Net loss was $69.8 million, or $0.72 per share, versus published expectations clustered around a $0.66–$0.68 loss. The miss is small, but there was no revenue contribution to offset the launch transition.

MetricQ1 FY2026Q1 FY2025 / prior periodExpectation or change
R&D expense$49.3M$57.8MDown $8.6M year over year
SG&A expense$19.0M$32.6MDown $13.6M year over year
Net loss$69.8M$86.7MNarrower reported loss
Diluted EPS$(0.72)$(0.95)Published consensus around $(0.66)–$(0.68)
Cash, equivalents and short-term investments$195.3M—Down from $268.9M at March 31, 2026

The main strategic news was already public before this filing. FDA approval of TUDRIQEV was announced on August 6, 2026, and the company had also recently completed a $150 million financing; this release mainly confirms the commercial transition rather than creating a fresh regulatory surprise. 〔0〕

The balance sheet is now positioned for launch, but dilution and spending are the trade-off. Management says the $141.0 million of net August financing proceeds, combined with existing liquidity, should fund operations for more than twelve months, including commercial scale-up and the IGNYTE-3 confirmatory trial.

The incremental operating signal is preparation, not proof of commercial execution. A new Chief Commercial Officer joins August 18, and product is expected in the U.S. market within 60 days, but the filing provides no early demand, reimbursement, or launch-revenue evidence yet. 〔1〕

Net read: a narrow earnings miss against a largely anticipated launch milestone. The approval and financing improve the company’s runway and readiness, but because both were already disclosed, the fresh quarterly result is principally a slightly larger-than-expected loss while investors wait for launch execution and confirmatory-trial validation.

What to watch next

TUDRIQEV U.S. launch within 60 days

Original filing on SEC EDGAR

More Replimune Group, Inc. news

The approval is old news; now the launch bill starts showing up | REPL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.